Pfizer has significantly bolstered its obesity and metabolic disease pipeline by agreeing to acquire Metsera for up to $7.3 billion, including contingent value rights based on clinical milestones. This follows Pfizer's earlier withdrawals from internal obesity drug programs due to safety concerns. Metsera's portfolio offers promising injectable and oral candidates that target metabolic pathways with potential dosing and tolerability advantages. The acquisition aligns Pfizer to compete more effectively in a rapidly growing obesity treatment market, reflecting renewed strategic focus under CEO Albert Bourla.